Diseases · Entity Annotation Prototype (beta)

16articles mentioning diseases

48disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: SLE-DAS ×

SLE-DAS

This disease is selected. Its supporting articles are shown below.

SLE-DAS16

Articles mentioning SLE-DAS

16 articles · page 2 of 2

PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis of anifrolumab trials

lupusscimed · abstract · 2026-03-01 · 2 matching annotations

98.5%

SLE lupus SLE-DAS LupusQoL anifrolumab BILAG-2004 AstraZeneca EQ-5D SLEDAI-2K SLEDAI

…ifrolumab trials (MUSE, TULIP-1, TULIP-2) in moderate-to-severe SLE. Physicians’ assessments (clinical and laboratory data, BILAG-2…

PO:09:225 Characterization of pulmonary involvement in systemic lupus erythematosus: insights from a multicentre Portuguese cohort

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

85.0%

Systemic Lupus Erythematosus SLE SLE-DAS oxygen therapy Portuguese Rheumatology Departments

… Pulmonary involvement is a frequent and significant feature of Systemic Lupus Erythematosus (SLE), although its clinical spectrum and outcomes remain poorl…

PO:11:281 Spanish real-world ambispective multicenter registry of anifrolumab in systemic lupus erythematosus: efficacy and safety at 3- and 6-month follow-up (ANIFRO-reu study)

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

92.9%

SLE systemic lupus erythematosus SLE-DAS SLEDAS COVID-19 herpes zoster Anifrolumab Spanish rheumatology centers

…1° In real-life clinical setting, anifrolumab improved multiple SLE activity measures at 3 and 6 months, with a substantial proport…

PO:11:302 Anifrolumab for systemic lupus erythematosus: preliminary safety and efficacy findings from the Italian experience

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

83.1%

Systemic Lupus Erythematosus SLE SLE-DAS Anifrolumab

…Objectives Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease. Anifrolumab, a monoclona…

Browse diseases

SLE-DAS

Articles mentioning SLE-DAS

PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis of anifrolumab trials

PO:09:225 Characterization of pulmonary involvement in systemic lupus erythematosus: insights from a multicentre Portuguese cohort

PO:11:281 Spanish real-world ambispective multicenter registry of anifrolumab in systemic lupus erythematosus: efficacy and safety at 3- and 6-month follow-up (ANIFRO-reu study)

PO:11:302 Anifrolumab for systemic lupus erythematosus: preliminary safety and efficacy findings from the Italian experience